Welcome to the e-CCO Library!

P683: Patients with newly diagnosed fistulizing perianal Crohn's disease have a distinct microbial signature
Year: 2021
Source: ECCO'21 Virtual
Authors: Goren, I.(1);Ian, W.(2);Reshef, L.(3);Sharar Fischler, T.(1);Pauker, M.(1);Silverman, J.(4);Dotan, I.(1);Yanai, H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P683: Risk factors for fatigue in IBD patients.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sina, M.(1)*;Djegsi, A.(1);Pemaj, X.(1);Telaku, S.(2);Babameto, A.(1);Prifti, S.(1);
Created: Friday, 14 July 2023, 11:12 AM
P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3, A. Armuzzi4, A.O. Damião5, N. Lawendy6, G. Solano7, K. Kwok8, J. Woolcott6, L. Salese6, C. Su6

Created: Thursday, 30 January 2020, 10:12 AM
P684: A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Taylor M.*1, Duggal A.1, Rowley A.1, Foster M.1, Sirohi S.1, Solanke Y.1, Walshe C.1, Webber S.1, Travis S.2, Irving P.3

Created: Wednesday, 20 February 2019, 10:36 AM
P684: Extra intravenous reinduction of ustekinumab on an already shortening interval is an effective optimisation strategy for patients with refractory Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yao, J.(1)*;Liu, T.(1);Min, Z.(1);
Created: Friday, 14 July 2023, 11:12 AM
P684: Increased risk of cardiovascular disease and high risk profiles compatible with metabolic syndrome in patients with Inflammatory Bowel Disease: a cross-sectional analysis of matched cohorts
Year: 2022
Source: ECCO'22
Authors: SleutjesAM, J.(1);Roeters van Lennep, J.E.(2);Kavousi, M.(3);Aribas, E.(3);van der Woude, C.J.(4);de Vries, A.C.(4);
Created: Friday, 11 February 2022, 3:56 PM
P684: Sleep disturbances in IBD patients without sedative therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.E. Gilca-Blanariu1,2*, G. Stefanescu1,2, M. Ciocoiu2

Created: Thursday, 21 February 2019, 9:14 AM
P684: Vaccination strategies for IBD patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Sitibondo*1, A. Squeri1, A. Viola1, G. Costantino1, A. Belvedere1, V. Pisana1, F. Costa2, R. Squeri2, W. Fries1

Created: Friday, 22 February 2019, 9:41 AM
P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel disease
Year: 2020
Source: ECCO'20 Vienna
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4
Created: Thursday, 30 January 2020, 10:12 AM
Last Modified: Wednesday, 3 March 2021, 4:11 PM by Dauren Ramankulov

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the following sentence in Results section should read: “The primary endpoint was not met.” instead of “The non-inferiority endpoint was met.”.

Upon the original publication, the final concluding remarks should read: “FM is associated with substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.” instead of “FM is associated with non-inferior efficacy and substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.”.

P685: Early use of infliximab after seton technique for patients with Crohn's disease who initially presented with perianal fistulas
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lim, K.Y.(1)*;Hwang, D.Y.(1);Lee, J.K.(1);
Created: Friday, 14 July 2023, 11:12 AM
P685: Gut microbiota in patients with Inflammatory Bowel Disease during remission
Year: 2021
Source: ECCO'21 Virtual
Authors: Pisani, A.(1);Rausch, P.(2);Ellul, S.(3);Bang, C.(2);Tabone, T.(1);Marantidis Cordina, C.(4);Zahra, G.(5);Ellul, P.(1);Franke, A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P685: Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. C. Dubinsky1, B. Bressler2, A. Armuzzi*3, L. Salese4, M. DiBonaventura5, E. Maller4, H. Fan4, D. A. Woodworth4, C. Su4

Created: Friday, 22 February 2019, 9:41 AM
P685: Patient’s performance and feedback by using home test faecal calprotectin as an objective reported outcome
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.C. Wei*

Created: Thursday, 21 February 2019, 9:14 AM
P685: Strong Response to SARS-CoV-2 Vaccine Additional Doses among Patients with Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Kappelman, M.(1);Weaver, K.(2);Zhang, X.(1);Chun, K.(3);Long, M.(2);
Created: Friday, 11 February 2022, 3:56 PM
P685: Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Huoponen S.*1, Eberl A.1,2, Räsänen P.1,2, Roine R.P.2,3, Sipponen T.1,2, Arkkila P.1,2, Blom M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P686 Expression of CD39 ectonucleotidase on regulatory T cells and on T helper 17 cells in children with IBD receiving anti-TNF therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S.V. Petrichuk1, Т. Radygina1, A. Illarionov2, D. Kuptsova1, A. Potapov3, A.P. Fisenko3

Created: Thursday, 30 January 2020, 10:12 AM
P686: Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Detrez I.*1, Ballet V.2, Van Assche G.2, Vermeire S.2, Ferrante M.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P686: Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: PRACTICROHN study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Barreiro-de Acosta1*, V. García2, A. Gutiérrez3, M.D. Martín Arranz4, M. Iborra5, C. Taxonera6, C. Romero7, B. Juliá7, L. Cea-Calvo7, E. Domènech8

Created: Thursday, 21 February 2019, 9:14 AM
P686: Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Kurent*1, U. Koren2, J. Hanzel1, M. Kozelj1, G. Novak1, N. Smrekar1, B. Stabuc1, N. Kecelj3, D. Drobne1

Created: Friday, 22 February 2019, 9:41 AM